2-(3-tert-butylpyrazol-1-id-5-yl)-6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazine;tetrakis(4-tert-butylpyridine);2-(5-ethyl-4-methylpyrazol-2-id-3-yl)-6-[3-(2-methylpropyl)-4-propan-2-ylpyrazol-1-id-5-yl]pyrazine;3-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-4,5,6,7-tetrahydroindazol-2-ide;5-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-1,10,10-trimethyl-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene;tetrakis(platinum(2+))

C111H140N28Pt4 — CID 157395241

IUPAC2-(3-tert-butylpyrazol-1-id-5-yl)-6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazine;tetrakis(4-tert-butylpyridine);2-(5-ethyl-4-methylpyrazol-2-id-3-yl)-6-[3-(2-methylpropyl)-4-propan-2-ylpyrazol-1-id-5-yl]pyrazine;3-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-4,5,6,7-tetrahydroindazol-2-ide;5-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-1,10,10-trimethyl-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene;tetrakis(platinum(2+))
SMILESCC(C)(C)c1ccncc1.CC(C)(C)c1ccncc1.CC(C)(C)c1ccncc1.CC(C)(C)c1ccncc1.CCc1n[n-]c(-c2cncc(-c3[n-]nc(CC(C)C)c3C(C)C)n2)c1C.CCc1n[n-]c(-c2cncc(-c3[n-]nc4c3C3CCC4(C)C3(C)C)n2)c1C.CCc1n[n-]c(-c2cncc(-c3[n-]nc4c3CCCC4)n2)c1C.CCc1n[n-]c(-c2cncc(-c3cc(C(C)(C)C)n[n-]3)n2)c1C.[Pt+2].[Pt+2].[Pt+2].[Pt+2]
InChIInChI=1S/C21H24N6.C20H26N6.C17H18N6.C17H20N6.4C9H13N.4Pt/c1-6-13-11(2)17(25-24-13)14-9-22-10-15(23-14)18-16-12-7-8-21(5,20(12,3)4)19(16)27-26-18;1-7-14-13(6)19(25-23-14)16-9-21-10-17(22-16)20-18(12(4)5)15(24-26-20)8-11(2)3;1-3-12-10(2)16(22-20-12)14-8-18-9-15(19-14)17-11-6-4-5-7-13(11)21-23-17;1-6-11-10(2)16(23-20-11)14-9-18-8-13(19-14)12-7-15(22-21-12)17(3,4)5;4*1-9(2,3)8-4-6-10-7-5-8;;;;/h9-10,12H,6-8H2,1-5H3;9-12H,7-8H2,1-6H3;8-9H,3-7H2,1-2H3;7-9H,6H2,1-5H3;4*4-7H,1-3H3;;;;/q4*-2;;;;;4*+2
InChIKeyBMMMVLCNZACWAP-UHFFFAOYSA-N
MW2646.85 g/mol
LogP21.72
Rot. Bonds15

About 2-(3-tert-butylpyrazol-1-id-5-yl)-6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazine;tetrakis(4-tert-butylpyridine);2-(5-ethyl-4-methylpyrazol-2-id-3-yl)-6-[3-(2-methylpropyl)-4-propan-2-ylpyrazol-1-id-5-yl]pyrazine;3-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-4,5,6,7-tetrahydroindazol-2-ide;5-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-1,10,10-trimethyl-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene;tetrakis(platinum(2+))

2-(3-tert-butylpyrazol-1-id-5-yl)-6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazine;tetrakis(4-tert-butylpyridine);2-(5-ethyl-4-methylpyrazol-2-id-3-yl)-6-[3-(2-methylpropyl)-4-propan-2-ylpyrazol-1-id-5-yl]pyrazine;3-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-4,5,6,7-tetrahydroindazol-2-ide;5-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-1,10,10-trimethyl-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene;tetrakis(platinum(2+)) (PubChem CID 157395241) has the molecular formula C111H140N28Pt4 and a molecular weight of 2646.85 g/mol. Its IUPAC name is 2-(3-tert-butylpyrazol-1-id-5-yl)-6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazine;tetrakis(4-tert-butylpyridine);2-(5-ethyl-4-methylpyrazol-2-id-3-yl)-6-[3-(2-methylpropyl)-4-propan-2-ylpyrazol-1-id-5-yl]pyrazine;3-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-4,5,6,7-tetrahydroindazol-2-ide;5-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-1,10,10-trimethyl-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene;tetrakis(platinum(2+)).

Molecular Properties

Compound Name2-(3-tert-butylpyrazol-1-id-5-yl)-6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazine;tetrakis(4-tert-butylpyridine);2-(5-ethyl-4-methylpyrazol-2-id-3-yl)-6-[3-(2-methylpropyl)-4-propan-2-ylpyrazol-1-id-5-yl]pyrazine;3-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-4,5,6,7-tetrahydroindazol-2-ide;5-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-1,10,10-trimethyl-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene;tetrakis(platinum(2+))
PubChem CID157395241
Molecular FormulaC111H140N28Pt4
Molecular Weight2646.85 g/mol
Exact Mass2645.04
IUPAC Name2-(3-tert-butylpyrazol-1-id-5-yl)-6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazine;tetrakis(4-tert-butylpyridine);2-(5-ethyl-4-methylpyrazol-2-id-3-yl)-6-[3-(2-methylpropyl)-4-propan-2-ylpyrazol-1-id-5-yl]pyrazine;3-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-4,5,6,7-tetrahydroindazol-2-ide;5-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-1,10,10-trimethyl-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene;tetrakis(platinum(2+))
SMILESCC(C)(C)c1ccncc1.CC(C)(C)c1ccncc1.CC(C)(C)c1ccncc1.CC(C)(C)c1ccncc1.CCc1n[n-]c(-c2cncc(-c3[n-]nc(CC(C)C)c3C(C)C)n2)c1C.CCc1n[n-]c(-c2cncc(-c3[n-]nc4c3C3CCC4(C)C3(C)C)n2)c1C.CCc1n[n-]c(-c2cncc(-c3[n-]nc4c3CCCC4)n2)c1C.CCc1n[n-]c(-c2cncc(-c3cc(C(C)(C)C)n[n-]3)n2)c1C.[Pt+2].[Pt+2].[Pt+2].[Pt+2]
InChIInChI=1S/C21H24N6.C20H26N6.C17H18N6.C17H20N6.4C9H13N.4Pt/c1-6-13-11(2)17(25-24-13)14-9-22-10-15(23-14)18-16-12-7-8-21(5,20(12,3)4)19(16)27-26-18;1-7-14-13(6)19(25-23-14)16-9-21-10-17(22-16)20-18(12(4)5)15(24-26-20)8-11(2)3;1-3-12-10(2)16(22-20-12)14-8-18-9-15(19-14)17-11-6-4-5-7-13(11)21-23-17;1-6-11-10(2)16(23-20-11)14-9-18-8-13(19-14)12-7-15(22-21-12)17(3,4)5;4*1-9(2,3)8-4-6-10-7-5-8;;;;/h9-10,12H,6-8H2,1-5H3;9-12H,7-8H2,1-6H3;8-9H,3-7H2,1-2H3;7-9H,6H2,1-5H3;4*4-7H,1-3H3;;;;/q4*-2;;;;;4*+2
InChIKeyBMMMVLCNZACWAP-UHFFFAOYSA-N
XLogP21.72
TPSA370.60 Ų
H-Bond Donors
H-Bond Acceptors20
Rotatable Bonds15
Heavy Atoms143
Complexity—

Lipinski Rule of Five

3 violations

RuleValue
MW ≤ 5002646.85
LogP ≤ 521.72
H-Bond Donors ≤ 50
H-Bond Acceptors ≤ 1020

Analyze 2-(3-tert-butylpyrazol-1-id-5-yl)-6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazine;tetrakis(4-tert-butylpyridine);2-(5-ethyl-4-methylpyrazol-2-id-3-yl)-6-[3-(2-methylpropyl)-4-propan-2-ylpyrazol-1-id-5-yl]pyrazine;3-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-4,5,6,7-tetrahydroindazol-2-ide;5-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-1,10,10-trimethyl-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene;tetrakis(platinum(2+)) with MolForge

Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.

Launch Full Analysis

Frequently Asked Questions

What is the IUPAC name of 2-(3-tert-butylpyrazol-1-id-5-yl)-6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazine;tetrakis(4-tert-butylpyridine);2-(5-ethyl-4-methylpyrazol-2-id-3-yl)-6-[3-(2-methylpropyl)-4-propan-2-ylpyrazol-1-id-5-yl]pyrazine;3-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-4,5,6,7-tetrahydroindazol-2-ide;5-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-1,10,10-trimethyl-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene;tetrakis(platinum(2+))?
The IUPAC name of 2-(3-tert-butylpyrazol-1-id-5-yl)-6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazine;tetrakis(4-tert-butylpyridine);2-(5-ethyl-4-methylpyrazol-2-id-3-yl)-6-[3-(2-methylpropyl)-4-propan-2-ylpyrazol-1-id-5-yl]pyrazine;3-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-4,5,6,7-tetrahydroindazol-2-ide;5-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-1,10,10-trimethyl-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene;tetrakis(platinum(2+)) (CID 157395241) is 2-(3-tert-butylpyrazol-1-id-5-yl)-6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazine;tetrakis(4-tert-butylpyridine);2-(5-ethyl-4-methylpyrazol-2-id-3-yl)-6-[3-(2-methylpropyl)-4-propan-2-ylpyrazol-1-id-5-yl]pyrazine;3-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-4,5,6,7-tetrahydroindazol-2-ide;5-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-1,10,10-trimethyl-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene;tetrakis(platinum(2+)).
What is the SMILES notation for 2-(3-tert-butylpyrazol-1-id-5-yl)-6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazine;tetrakis(4-tert-butylpyridine);2-(5-ethyl-4-methylpyrazol-2-id-3-yl)-6-[3-(2-methylpropyl)-4-propan-2-ylpyrazol-1-id-5-yl]pyrazine;3-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-4,5,6,7-tetrahydroindazol-2-ide;5-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-1,10,10-trimethyl-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene;tetrakis(platinum(2+))?
The canonical SMILES for 2-(3-tert-butylpyrazol-1-id-5-yl)-6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazine;tetrakis(4-tert-butylpyridine);2-(5-ethyl-4-methylpyrazol-2-id-3-yl)-6-[3-(2-methylpropyl)-4-propan-2-ylpyrazol-1-id-5-yl]pyrazine;3-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-4,5,6,7-tetrahydroindazol-2-ide;5-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-1,10,10-trimethyl-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene;tetrakis(platinum(2+)) is CC(C)(C)c1ccncc1.CC(C)(C)c1ccncc1.CC(C)(C)c1ccncc1.CC(C)(C)c1ccncc1.CCc1n[n-]c(-c2cncc(-c3[n-]nc(CC(C)C)c3C(C)C)n2)c1C.CCc1n[n-]c(-c2cncc(-c3[n-]nc4c3C3CCC4(C)C3(C)C)n2)c1C.CCc1n[n-]c(-c2cncc(-c3[n-]nc4c3CCCC4)n2)c1C.CCc1n[n-]c(-c2cncc(-c3cc(C(C)(C)C)n[n-]3)n2)c1C.[Pt+2].[Pt+2].[Pt+2].[Pt+2].
What is the InChIKey of 2-(3-tert-butylpyrazol-1-id-5-yl)-6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazine;tetrakis(4-tert-butylpyridine);2-(5-ethyl-4-methylpyrazol-2-id-3-yl)-6-[3-(2-methylpropyl)-4-propan-2-ylpyrazol-1-id-5-yl]pyrazine;3-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-4,5,6,7-tetrahydroindazol-2-ide;5-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-1,10,10-trimethyl-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene;tetrakis(platinum(2+))?
The InChIKey is BMMMVLCNZACWAP-UHFFFAOYSA-N. The full InChI is InChI=1S/C21H24N6.C20H26N6.C17H18N6.C17H20N6.4C9H13N.4Pt/c1-6-13-11(2)17(25-24-13)14-9-22-10-15(23-14)18-16-12-7-8-21(5,20(12,3)4)19(16)27-26-18;1-7-14-13(6)19(25-23-14)16-9-21-10-17(22-16)20-18(12(4)5)15(24-26-20)8-11(2)3;1-3-12-10(2)16(22-20-12)14-8-18-9-15(19-14)17-11-6-4-5-7-13(11)21-23-17;1-6-11-10(2)16(23-20-11)14-9-18-8-13(19-14)12-7-15(22-21-12)17(3,4)5;4*1-9(2,3)8-4-6-10-7-5-8;;;;/h9-10,12H,6-8H2,1-5H3;9-12H,7-8H2,1-6H3;8-9H,3-7H2,1-2H3;7-9H,6H2,1-5H3;4*4-7H,1-3H3;;;;/q4*-2;;;;;4*+2.
What are the key properties of 2-(3-tert-butylpyrazol-1-id-5-yl)-6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazine;tetrakis(4-tert-butylpyridine);2-(5-ethyl-4-methylpyrazol-2-id-3-yl)-6-[3-(2-methylpropyl)-4-propan-2-ylpyrazol-1-id-5-yl]pyrazine;3-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-4,5,6,7-tetrahydroindazol-2-ide;5-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-1,10,10-trimethyl-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene;tetrakis(platinum(2+))?
2-(3-tert-butylpyrazol-1-id-5-yl)-6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazine;tetrakis(4-tert-butylpyridine);2-(5-ethyl-4-methylpyrazol-2-id-3-yl)-6-[3-(2-methylpropyl)-4-propan-2-ylpyrazol-1-id-5-yl]pyrazine;3-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-4,5,6,7-tetrahydroindazol-2-ide;5-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-1,10,10-trimethyl-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene;tetrakis(platinum(2+)) has a molecular weight of 2646.85 g/mol, XLogP of 21.72, 15 rotatable bonds, 0 hydrogen bond donors, and 20 hydrogen bond acceptors.
Where does this data come from?
All data for 2-(3-tert-butylpyrazol-1-id-5-yl)-6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazine;tetrakis(4-tert-butylpyridine);2-(5-ethyl-4-methylpyrazol-2-id-3-yl)-6-[3-(2-methylpropyl)-4-propan-2-ylpyrazol-1-id-5-yl]pyrazine;3-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-4,5,6,7-tetrahydroindazol-2-ide;5-[6-(5-ethyl-4-methylpyrazol-2-id-3-yl)pyrazin-2-yl]-1,10,10-trimethyl-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene;tetrakis(platinum(2+)) is sourced from PubChem (CID 157395241), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).